Neuronetics Inc (STIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuronetics Inc (STIM) has a cash flow conversion efficiency ratio of -0.552x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.42 Million) by net assets ($17.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neuronetics Inc (STIM) market capitalisation for the company's overall valuation and market capitalisation.
Neuronetics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Neuronetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neuronetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuronetics Inc ranked by their cash flow conversion efficiency. See Neuronetics Inc (STIM) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Research Alliance Corporation III Class A Ordinary Shares
NASDAQ:RACC
|
N/A |
|
Big River Industries Ltd
AU:BRI
|
0.084x |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
0.015x |
|
Vistin Pharma ASA
OL:VISTN
|
-0.010x |
|
Kyungin Synthe
KO:012610
|
0.066x |
|
Biotalys NV
BR:BTLS
|
-0.154x |
|
Koryo Credit Information Co. Ltd
KQ:049720
|
0.133x |
|
Tomer Energy Royalties (2012) Ltd
TA:DLRL
|
0.063x |
Annual Cash Flow Conversion Efficiency for Neuronetics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Neuronetics Inc from 2016 to 2025. View Neuronetics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.24 Million | $-20.37 Million | -0.776x | +20.35% |
| 2024-12-31 | $31.80 Million | $-31.00 Million | -0.975x | -4.03% |
| 2023-12-31 | $34.19 Million | $-32.04 Million | -0.937x | -73.94% |
| 2022-12-31 | $57.06 Million | $-30.74 Million | -0.539x | -63.97% |
| 2021-12-31 | $85.17 Million | $-27.98 Million | -0.329x | +70.50% |
| 2020-12-31 | $25.49 Million | $-28.39 Million | -1.114x | -74.82% |
| 2019-12-31 | $47.85 Million | $-30.48 Million | -0.637x | -119.78% |
| 2018-12-31 | $71.04 Million | $-20.59 Million | -0.290x | -601.07% |
| 2017-12-31 | $-192.65 Million | $-11.14 Million | 0.058x | +19.96% |
| 2016-12-31 | $-177.12 Million | $-8.54 Million | 0.048x | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more